US FDA To Explore New Regulatory Pathways For Some Cellular Products
CBER Director Peter Marks says FDA plans to explore whether there is an intermediate pathway between tissue regulations and a full BLA for certain cellular products. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, Getty images
